GO:0005151 interleukin-1, type II receptor binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0005151 describes the molecular function of binding to the Type II interleukin-1 receptor (IL-1R2), a decoy receptor that sequesters IL-1 ligands.
• IL-1R2 acts as a decoy target for IL-1, preventing signal transduction through the Type I receptor and thereby dampening inflammation.
• The term is central to the interleukin-1 pathway, a key mediator of innate immunity and inflammation.
• IL-1R2 is regulated by cytokines such as IL-4 and is shed as a soluble form that can be measured in circulation [6,8].
• Dysregulation of IL-1R2 binding is implicated in kidney disease and other inflammatory conditions.
• CRISPR-based models (knockout, knock-in, overexpression) enable precise dissection of IL-1R2 binding and its downstream effects.
Description
Interleukin-1 (IL-1) is a master cytokine of innate immunity, and its activity is tightly controlled by a family of receptors and decoy proteins. The Type II interleukin-1 receptor (IL-1R2) is a unique member of this family because it lacks a signaling cytoplasmic domain and functions primarily as a decoy target for IL-1. The Gene Ontology term GO:0005151, interleukin-1, type II receptor binding, describes the molecular function of proteins that bind to IL-1R2, thereby modulating IL-1 availability and signaling. This function is critical for understanding how the IL-1 system is regulated and how imbalances contribute to inflammatory diseases [1,7]. Researchers studying inflammation, autoimmunity, and kidney disease are increasingly interested in IL-1R2 binding as a therapeutic target and biomarker [7,8].
interleukin-1, type II receptor binding At A Glance
| GO ID | GO:0005151 |
|---|---|
| GO term | interleukin-1, type II receptor binding |
| Ontology | molecular_function |
| Synonym | IL-1 type II; interleukin-1, type II receptor ligand |
| Major function | Binding to the Type II interleukin-1 receptor (IL-1R2), acting as a decoy to sequester IL-1 and inhibit signaling |
| Cellular location | Cell membrane; soluble form in extracellular space |
| Regulation | Induced by IL-4 and other cytokines; shed by proteases |
| Disease relevance | Inflammation, kidney disease, and immune regulation |
What Is GO:0005151?
GO:0005151 is defined as the binding to a Type II interleukin-1 receptor. In practice, this means the physical interaction between a ligand (such as IL-1α or IL-1β) or another protein and the IL-1R2 receptor, which can occur on the cell surface or in soluble form. This binding event is a molecular function that modulates the availability of IL-1 for signaling through the Type I receptor.
Why Is interleukin-1, type II receptor binding Important in Cell Biology?
Understanding GO:0005151 is essential because IL-1R2 acts as a natural brake on IL-1 signaling, and its binding properties determine the intensity and duration of inflammatory responses. Dysregulation of this decoy system has been linked to chronic inflammatory diseases, including kidney injury, and to the response to immunotherapy [7,8]. Moreover, the soluble form of IL-1R2 is a potential biomarker for immune activation. Thus, studying this molecular function provides insights into basic immunology and offers opportunities for therapeutic intervention.
• IL-1R2 binding sequesters IL-1, preventing excessive inflammation.
• It is a key regulatory node in the IL-1 pathway, which is central to innate immunity.
• Soluble IL-1R2 levels are elevated in patients receiving IL-2 immunotherapy, indicating immune activation.
• IL-1R2 is implicated in kidney disease, where it may protect against or contribute to injury.
• The decoy function of IL-1R2 can be exploited to design anti-inflammatory therapeutics.
• CRISPR screens can identify regulators of IL-1R2 binding and shedding.
• IL-1R2 binding affects the balance between pro- and anti-inflammatory signals.
• Understanding this function aids in interpreting cytokine networks in autoimmune diseases.
What Happens During interleukin-1, type II receptor binding?
Ligand recognition and binding
In simple terms: IL-1 molecules dock onto the IL-1R2 receptor like a key in a lock, but the lock has no handle to open the door.
The Type II IL-1 receptor (IL-1R2) binds IL-1α and IL-1β with high affinity, competing with the signaling Type I receptor (IL-1R1). This binding is the first step in the decoy function, effectively reducing the concentration of free IL-1 available to trigger inflammation.
Decoy function and signal inhibition
In simple terms: By soaking up IL-1, IL-1R2 acts like a sponge that prevents the cytokine from reaching its active receptor.
Because IL-1R2 lacks a cytoplasmic signaling domain (TIR domain), binding of IL-1 does not lead to NF-κB activation or inflammatory gene expression. Instead, it sequesters the ligand, thereby inhibiting IL-1 signaling through IL-1R1.
Shedding and soluble form
In simple terms: The receptor can be cut off the cell surface and float in the blood, where it continues to trap IL-1.
IL-1R2 can be proteolytically cleaved to generate a soluble form (sIL-1R2) that retains ligand-binding capacity and circulates in the bloodstream. Elevated sIL-1R2 levels have been observed during IL-2 immunotherapy, reflecting immune activation.
Regulation by cytokines
In simple terms: Other immune signals, like IL-4, can turn up the production of this decoy receptor.
IL-4 induces the expression of IL-1R2, thereby enhancing the decoy capacity and contributing to the resolution of inflammation. This regulation links Th2-type responses to the suppression of IL-1-driven inflammation.
Key Genes Involved in GO:0005151 interleukin-1, type II receptor binding
The following genes and proteins are directly involved in or regulate interleukin-1, type II receptor binding and its downstream effects.
| Gene | Major Role | Research Relevance |
|---|---|---|
| IL1R2 | Encodes the Type II IL-1 receptor (decoy receptor) | Central to GO:0005151; target for knockout/knock-in studies |
| IL1B | Pro-inflammatory cytokine ligand for IL-1R2 | Binding partner; key mediator of inflammation |
| IL1A | Another IL-1 ligand that binds IL-1R2 | Alternative ligand; less studied but relevant |
| IL1R1 | Type I IL-1 receptor, signaling receptor | Competes with IL-1R2 for IL-1; target for pathway analysis |
| IL1RN | IL-1 receptor antagonist | Modulates IL-1 availability; interacts with pathway |
| IL4 | Cytokine that induces IL1R2 expression | Regulator of decoy receptor levels |
| IL2 | Cytokine used in immunotherapy | Induces soluble IL-1R2 in patients |
| NFKB1 | Transcription factor downstream of IL-1R1 | Readout of IL-1 signaling; not activated by IL-1R2 |
| MYD88 | Adaptor protein for IL-1R1 signaling | Not recruited by IL-1R2; key differentiator |
| IRAK4 | Kinase in IL-1R1 pathway | Downstream of signaling receptor; not involved in decoy |
| TRAF6 | E3 ubiquitin ligase in IL-1R1 pathway | Signaling node; absent in IL-1R2 complexes |
| ADAM17 | Protease that sheds IL-1R2 | Generates soluble decoy receptor |
| TIRAP | Adaptor protein in IL-1R1 signaling | Not recruited by IL-1R2 |
| SOCS3 | Negative regulator of cytokine signaling | May modulate IL-1 pathway cross-talk |
| NLRP3 | Inflammasome component that activates IL-1β | Upstream of IL-1β; links to IL-1R2 binding |
| GSDMD | Gasdermin D, mediates IL-1β release | Upstream of ligand availability |
| P2RX7 | Purinergic receptor that triggers IL-1β release | Regulates ligand levels for IL-1R2 |
How Is interleukin-1, type II receptor binding Regulated?
The expression and function of IL-1R2 are regulated at multiple levels. Cytokines such as IL-4 induce IL1R2 transcription, increasing decoy receptor availability. Proteolytic shedding by enzymes like ADAM17 generates a soluble form that can be measured in serum. In immunotherapy, IL-2 administration leads to elevated circulating soluble IL-1R2, indicating systemic immune activation. Additionally, the balance between IL-1R1 and IL-1R2 determines the net inflammatory response to IL-1.
interleukin-1, type II receptor binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| IL1R2 | Kidney disease | IL1R2 knockout mouse; kidney injury models |
| IL1B | Autoinflammatory diseases | IL1B knock-in mice; CRISPR point mutations |
| IL1RN | DIRA (deficiency of IL-1 receptor antagonist) | IL1RN knockout; overexpression models |
| IL4 | Allergic inflammation | IL4 knockout; IL1R2 reporter |
| ADAM17 | Inflammatory shedding | ADAM17 knockout; shedding assays |
IL-1R2 in Kidney Disease
IL-1R2 has been implicated in kidney disease, where it may act as a protective decoy by limiting IL-1-mediated injury. Studies suggest that modulating IL-1R2 binding could be a therapeutic strategy in renal inflammation.
IL-1R2 in Inflammatory and Autoimmune Conditions
Dysregulation of the IL-1 decoy system contributes to chronic inflammatory diseases. Reduced IL-1R2 function can lead to excessive IL-1 signaling, exacerbating conditions such as rheumatoid arthritis and inflammatory bowel disease.
IL-1R2 as a Biomarker in Immunotherapy
Elevated levels of soluble IL-1R2 during IL-2 immunotherapy indicate immune activation and may serve as a pharmacodynamic marker. This highlights the clinical relevance of IL-1R2 binding in monitoring treatment responses.
From interleukin-1, type II receptor binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does IL1R2 knockout increase IL-1 signaling? | IL1R2 knockout cell line (e.g., HEK293, THP-1) |
| What is the effect of a point mutation in IL1R2 on ligand binding? | CRISPR point-mutation knock-in of IL1R2 |
| Can we tag endogenous IL1R2 for imaging? | Knock-in of fluorescent tag (e.g., GFP) at IL1R2 locus |
| Does overexpression of IL1R2 suppress inflammation? | IL1R2 overexpression lentiviral model |
| Which genes regulate IL1R2 shedding? | CRISPR library screening with shedding readout |
| How does soluble IL1R2 affect immune cells? | Recombinant sIL-1R2 treatment in vitro |
How to Study the interleukin-1, type II receptor binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Surface plasmon resonance (SPR) | Binding affinity and kinetics | Characterize IL-1/IL-1R2 interaction |
| CRISPR knockout screening | Gene essentiality for IL-1R2 function | Identify regulators of decoy activity |
| RNA-seq | Transcriptional changes | Profile IL1R2 and pathway genes |
| Flow cytometry | Cell-surface IL-1R2 levels | Quantify binding in cell lines |
| ELISA | Soluble IL-1R2 concentration | Measure sIL-1R2 in serum |
| Western blot | Protein expression and shedding | Detect IL-1R2 cleavage |
| Luciferase reporter assay | NF-κB activation | Assess functional impact of IL-1R2 binding |
| Co-immunoprecipitation | Protein-protein interactions | Confirm IL-1R2 binding partners |
Binding Assays
Surface plasmon resonance (SPR) and isothermal titration calorimetry (ITC) can measure the affinity of IL-1 ligands for IL-1R2, providing quantitative data on GO:0005151.
CRISPR Screening
Genome-wide CRISPR knockout or activation screens can identify regulators of IL-1R2 expression, shedding, or binding, using readouts such as IL-1-induced NF-κB reporter activity.
Transcriptomics and Proteomics
RNA-seq and mass spectrometry can profile changes in IL1R2 and related pathway genes upon perturbation, revealing downstream effects of altered binding.
Flow Cytometry and Imaging
Flow cytometry with fluorescently labeled IL-1 can detect cell-surface IL-1R2 binding, while imaging can visualize receptor internalization or co-localization.
How CRISPR Can Be Used to Study GO:0005151 interleukin-1, type II receptor binding
Knockout
CRISPR knockout of IL1R2 eliminates the decoy receptor, leading to enhanced IL-1 signaling. This model is useful to study the consequences of loss of GO:0005151 function in inflammation and disease.
Point Mutation
Introducing point mutations in the ligand-binding domain of IL1R2 can dissect residues critical for IL-1 binding, providing mechanistic insights into GO:0005151.
Knock-in
Knock-in of epitope tags or fluorescent proteins at the endogenous IL1R2 locus allows real-time tracking of receptor localization and binding without overexpression artifacts.
Overexpression
Overexpression of IL1R2 using lentiviral or transgenic systems can amplify the decoy effect, serving as a gain-of-function model to test anti-inflammatory strategies.
How EDITGENE Supports interleukin-1, type II receptor binding Research
Researchers studying interleukin-1, type II receptor binding-related genes often need to determine whether a candidate gene is causally involved in the decoy function or downstream inflammatory responses. EDITGENE provides a comprehensive suite of CRISPR-based services to enable such investigations with precision and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for interleukin-1, type II receptor binding research.
Frequently Asked Questions About interleukin-1, type II receptor binding
What is GO:0005151?
GO:0005151 is the Gene Ontology term for interleukin-1, type II receptor binding, a molecular function describing the binding to the Type II interleukin-1 receptor (IL-1R2).
What genes are involved in interleukin-1, type II receptor binding?
Key genes include IL1R2 (the receptor), IL1B and IL1A (ligands), and regulators such as IL4 and ADAM17 [1,6].
What is the function of IL-1R2?
IL-1R2 acts as a decoy receptor that binds IL-1 and prevents it from signaling through the Type I receptor, thereby dampening inflammation.
How is IL-1R2 regulated?
IL-1R2 expression is induced by IL-4 and can be shed by proteases like ADAM17 to produce a soluble form.
What diseases are associated with IL-1R2?
IL-1R2 has been implicated in kidney disease, inflammatory conditions, and as a biomarker in immunotherapy [7,8].
How can I study interleukin-1, type II receptor binding?
Methods include SPR, CRISPR screening, flow cytometry, and ELISA for soluble IL-1R2 [6,8].
What is the role of IL-1R2 in inflammation?
By sequestering IL-1, IL-1R2 limits the activation of inflammatory pathways, acting as a natural brake.
Can CRISPR be used to study IL-1R2?
Yes, CRISPR knockout, knock-in, and overexpression models are powerful tools to dissect IL-1R2 function.
What is soluble IL-1R2?
Soluble IL-1R2 is the extracellular domain of IL-1R2 shed from the cell surface; it retains ligand-binding capacity and circulates in blood [6,8].
Why is IL-1R2 important in immunotherapy?
Elevated soluble IL-1R2 levels during IL-2 immunotherapy indicate immune activation and may serve as a pharmacodynamic marker.
Conclusion
GO:0005151, interleukin-1, type II receptor binding, represents a critical regulatory mechanism in the IL-1 system. The decoy receptor IL-1R2 binds IL-1 ligands, preventing excessive inflammation and maintaining immune homeostasis. Dysregulation of this function is linked to kidney disease and other inflammatory conditions, and soluble IL-1R2 is a promising biomarker [7,8]. Advances in CRISPR technology now allow precise interrogation of this molecular function, paving the way for novel therapeutic strategies.
References
- 1. Weber A et al.. 2010. Interleukin-1 (IL-1) pathway.. Sci Signal 3(105):cm1 PMID: 20086235
- 4. Bambouskova M et al.. 2021. Itaconate confers tolerance to late NLRP3 inflammasome activation.. Cell Rep 34(10):108756 PMID: 33691097
- 6. Colotta F et al.. 1993. Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4.. Science 261(5120):472-5 PMID: 8332913
- 7. Hu H et al.. 2024. Role of Interleukin 1 Receptor 2 in Kidney Disease.. J Interferon Cytokine Res 44(4):170-177 PMID: 38527174
- 8. Vannier E et al.. 1999. Elevated circulating levels of soluble interleukin-1 receptor type II during interleukin-2 immunotherapy.. Eur Cytokine Netw 10(1):37-42 PMID: 10210771
